RESIDENCY

Question 1

When to do ABG after hooking to mech vent

Answer 1

Within an hour

Question 2

Mech vent: How to set TV

Answer 2

6-8cc/kg

Question 3

Mech vent: How to set FiO2

Answer 3

Begin wih 100, wean as tolerated

Question 4

Mech vent: How to set PEEP

Answer 4

Begin with 5

Question 5

ABG parameter to measure oxygenation

Answer 5

PO2

Question 6

ABG parameter to measure ventilation

Answer 6

PCO2

Question 7

Parameters to manipulate to alter oxygenation (PO2)

Answer 7

1) FiO2
2) PEEP
3) I-time

Question 8

Parameters to manipulate to alter ventilation (PCO2)

Answer 8

1) RR
2) TV
3) Shorten I-time to lengthen E-time

Question 9

Proper ET size

Answer 9

(Age/4) + 4 OR

Question 10

ET length

Answer 10

Size x 3 OR
Wt. + 6 OR
(Age/2) + 12

Question 11

Mech vent: How to set rate

Answer 11

Infant: 25-30/min
Child: 15-20/min
Teen: 10-14/min

Question 12

Incidence of hemophilia A

Answer 12

1/10,000 male births

Question 13

Incidence of hemophilia B

Answer 13

1/30,000 male births

Question 14

Symptomatic female carriers of hemophilia A

Answer 14

30%

Question 15

Factors that increase risk of inhibitor development

Answer 15

Surgery
Infection
Most important: Genetics (gene mutation)

Question 16

% factor activity goal in hemophilia in Phils in factor transfusion

Answer 16

60-80%

100% in developed countries

Question 17

% factor activity for adequate hemostasis (hemophilia)

Answer 17

30%

Question 18

How to screen for inhibitors in patients with hemophilia

Answer 18

Mixing studies (px plasma + normal plasma –> aPtt: 60% increase from baseline = no inhibitor)

Question 19

Indications for admission of hemophiliac patients

Answer 19

1) Life-threatening bleed (excluding hemarthroses)

2) Non-life-threatening bleed IF known to have inhibitor

Question 20

Phenobarbital, side effect (WOF when loading)

Answer 20

Respiratory depression

Question 21

Incidence of hemophilia A

Answer 21

1/10,000 male birthd

Question 22

Incidence of hemophilia B

Answer 22

1/30,000 male births

Question 23

Symptomatic female carriers of hemophilia A

Answer 23

30%

Question 24

Factors that increase risk of inhibitor development

Answer 24

Surgery
Infection
Most important: Genetics (gene mutation)

Question 25

% factor activity goal in hemophilia in Phils in factor transfusion

Answer 25

60-80% | 100% in developed countries

Question 26

% factor activity for adequate hemostasis (hemophilia)

Answer 26

30%

Question 27

How to screen for inhibitors in patients with hemophilia

Answer 27

Mixing studies (px plasma + normal plasma --> aPtt: 60% increase from baseline = no inhibitor)

Question 28

Indications for admission of hemophiliac patients

Answer 28

1) Life-threatening bleed (excluding hemarthroses) | 2) Non-life-threatening bleed IF known to have inhibitor

Question 29

Phenobarbital, side effect (WOF when loading)

Answer 29

Respiratory depression

Question 30

Incidence of hemophilia A

Answer 30

1/10,000 male birthd

Question 31

Incidence of hemophilia B

Answer 31

1/30,000 male births

Question 32

Symptomatic female carriers of hemophilia A

Answer 32

30%

Question 33

Factors that increase risk of inhibitor development

Answer 33

Surgery Infection Most important: Genetics (gene mutation)

Question 34

% factor activity goal in hemophilia in Phils in factor transfusion

Answer 34

60-80% | 100% in developed countries

Question 35

% factor activity for adequate hemostasis (hemophilia)

Answer 35

30%

Question 36

How to screen for inhibitors in patients with hemophilia

Answer 36

Mixing studies (px plasma + normal plasma --> aPtt: 60% increase from baseline = no inhibitor)

Question 37

Indications for admission of hemophiliac patients

Answer 37

1) Life-threatening bleed (excluding hemarthroses) | 2) Non-life-threatening bleed IF known to have inhibitor

Question 38

Phenobarbital, side effect (WOF when loading)

Answer 38

Respiratory depression